Physician profile
Sergio G Arancibia
NPI 1881926939
$13,480.58
in general payments reported to CMS, 2019-2025
68 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,525 · 2022: $3,468 · 2023: $3,644 · 2024: $1,120 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,703 · Education: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,702.99 |
| Education | $784.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,373.03 | 2021-2025 | |
| Astellas Pharma US INC | $806.90 | 2021-2024 | Xospata, Xtandi, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $727.30 | 2021-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $685.38 | 2021-2025 | Imbruvica, Tremfya, Darzalex |
| Incyte Corporation | $540.04 | 2021-2025 | Jakafi, Opzelura |
| Eisai INC. | $536.94 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $530.75 | 2021-2023 | Ninlaro, Alunbrig, Fruzaqla |
| Amgen INC. | $471.29 | 2021-2025 | Otezla, Lumakras |
| Abbvie INC. | $464.93 | 2021-2025 | |
| Seagen INC. | $424.06 | 2021-2023 | Adcetris, Padcev, Tivdak |
| Merck Sharp & Dohme LLC | $403.28 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $385.82 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $354.72 | 2021-2025 | Lynparza, Enhertu, Calquence |
| Celgene Corporation | $354.50 | 2021-2024 | Reblozyl, Pomalyst |
| Genzyme Corporation | $329.25 | 2021-2025 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Arancibia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.